Resource Summary Report

Generated by Kravitz on Sep 10, 2026

IUPHAR/BPS Guide to Pharmacology

RRID:SCR_013077
Type: Tool

Proper Citation

IUPHAR/BPS Guide to Pharmacology (RRID:SCR_013077)

Resource Information

URL: http://www.guidetopharmacology.org

Proper Citation: IUPHAR/BPS Guide to Pharmacology (RRID:SCR_013077)

Description: Portal and searchable database of pharmacological information. Information is presented at two levels, the initial view or landing pages for each target family provide expert-curated overviews of the key properties and the available selective ligands and tool compounds. For selected targets, more detailed introductory chapters for each family are available along with curated information on the pharmacological, physiological, structural, genetic and pathophysiogical properties of each target.

Abbreviations: IUPHAR Database, IUPHAR-DB, IUPHAR GPCR, IUPHAR RECEPTOR

Synonyms: International Union of Pharmacology Database, International Union of Basic and Clinical Pharmacology Database

Resource Type: data or information resource, database, narrative resource, portal, standard specification

Defining Citation: PMID:21087994

Keywords: pharmacology, drug discovery, portal, guide, physiology, molecular structure, bio.tools, FASEB list

Funding: Wellcome Trust

Resource Name: IUPHAR/BPS Guide to Pharmacology

Resource ID: SCR_013077

Alternate IDs: nif-0000-03056, biotools:iuphar-db, r3d100013308

Alternate URLs: https://bio.tools/iuphar-db, https://doi.org/10.17616/R31NJMRG

Old URLs: http://www.iuphar-db.org

Record Creation Time: 20220129T080314+0000

Record Last Update: 20260905T132732+0000

Ratings and Alerts

No rating or validation information has been found for IUPHAR/BPS Guide to Pharmacology.

No alerts have been found for IUPHAR/BPS Guide to Pharmacology.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 2375 mentions in open access literature.

Listed below are recent publications. The full list is available at Kravitz .

Suarez-Kurtz G, et al. (2026) Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. British journal of clinical pharmacology, 92(1), 109.

Wang F, et al. (2026) Microglial HVCN1 Deficiency Improves Movement and Survival of SOD1G93A ALS Mice by Enhancing Microglial Migration and Neuroprotection. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e12149.

Ali M, et al. (2026) Unravelling Tinengotinib's Mechanistic Landscape in Triple-Negative Breast Cancer Via Network Pharmacology and in Silico Simulation Techniques. Cell biochemistry and biophysics, 84(1), 873.

Alzeer S, et al. (2026) Short communication: Dynamic chemical labelling allows the measurement of the paracetamol toxicity biomarker microRNA-122 in hospital clinical laboratories. British journal of clinical pharmacology, 92(2), 612.

Lin S, et al. (2026) Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment. British journal of clinical pharmacology, 92(3), 903.

Yang YO, et al. (2026) Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. British journal of clinical pharmacology, 92(5), 1339.

Leding AAM, et al. (2026) Population pharmacokinetics of TBAJ-587 and its main metabolites-Evaluation of different loading dose strategies and early dose selection. British journal of clinical pharmacology, 92(4), 1058.

Asiimwe IG, et al. (2026) APOE genotype and the effect of statins on lipid outcomes: A meta-analysis. British journal of clinical pharmacology, 92(5), 1268.

Thomas CM, et al. (2026) Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data. British journal of clinical pharmacology, 92(7), 2136.

Xia C, et al. (2026) Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals. British journal of clinical pharmacology, 92(5), 1473.

Berres J, et al. (2026) The quantitative impact of metabolism-inhibiting drugs on the occurrence of adverse drug reactions-A backward selection approach. British journal of clinical pharmacology, 92(7), 2203.

Daniele G, et al. (2026) Main factors associated with variability in the assessment of the objective response rate. A re-analysis of the PHEREXA phase 3 clinical trial. British journal of clinical pharmacology, 92(6), 1894.

Damkier P, et al. (2026) Paternal use of metformin and risk of major congenital malformations: A meta-analysis of 4 studies. British journal of clinical pharmacology, 92(6), 1940.

Widiapradja A, et al. (2026) Neurokinin-1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice. British journal of pharmacology, 183(15), 4246.

Hsu CC, et al. (2026) Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study. British journal of clinical pharmacology, 92(1), 220.

Ding J, et al. (2026) Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. British journal of clinical pharmacology, 92(2), 589.

Storgaard IK, et al. (2026) Population pharmacokinetic modelling revealed large variability in oromucosal absorption of ??9-tetrahydrocannabinol in older patients with poor appetite. British journal of clinical pharmacology, 92(2), 504.

Hutchins H, et al. (2026) Developing medication independence: The experience of UK teenagers. British journal of clinical pharmacology, 92(7), 2127.

Hoffmann M, et al. (2026) Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells. British journal of clinical pharmacology, 92(7), 2075.

Chen H, et al. (2026) Automatically Defining Protein Words for Diverse Functional Predictions Based on Attention Analysis of a Protein Language Model. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(21), e21970.